Skip to content

Alexion Pharmaceuticals closes a $111 million cash deal for Taligen assets

Alexion Pharmaceuticals has announced an all stock purchase of Taligen Therapeutics, a privately held company based in Cambridge, Massachusetts. The all cash upfront deal for $111M may reflect, in part, a considerable market interest in potential AMD compounds, including those at an early pre-clinical stage. Additional contingent payments of approximately $267M could be earned upon reaching various clinical efficacy and product approval milestones in the US and EU markets for a number of key products.